In the study of cognitive improvement by dexmedetomidine (Dex) in AD patients, the miR-129/YAP1/JAG1 axis may be a potential mechanism by which Dex protects against cognitive impairment in AD patients (Sun et al., 2020). This evidence concerns the gene JAG1 and Alzheimer disease.